Skip to main content

Provention Bio, Inc. (PRVB)

NASDAQ: PRVB · IEX Real-Time Price · USD
6.11 -0.10 (-1.61%)
Oct 22, 2021 10:04 AM EDT - Market open
Market Cap393.56M
Revenue (ttm)n/a
Net Income (ttm)-125.46M
Shares Out63.38M
EPS (ttm)-2.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume35,809
Open6.18
Previous Close6.21
Day's Range6.11 - 6.23
52-Week Range5.59 - 20.05
Beta2.96
AnalystsBuy
Price Target15.64 (+156.0%)
Est. Earnings DateNov 4, 2021

About PRVB

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treat...

IndustryPharmaceuticals
CEOAshleigh Palmer
Employees59
Stock ExchangeNASDAQ
Ticker SymbolPRVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Provention Bio stock is "Buy." The 12-month stock price forecast is 15.64, which is an increase of 155.97% from the latest price.

Price Target
$15.64
(155.97% upside)
Analyst Consensus: Buy

News

Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021

RED BANK, N.J., Sept. 23, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that man...

4 weeks ago - PRNewsWire

Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

RED BANK, N.J., Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that man...

1 month ago - PRNewsWire

Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License ...

RED BANK, N.J., Sept. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update...

1 month ago - PRNewsWire

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols:AVIRHSTONRBONVIVSYN
1 month ago - InvestorPlace

Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 9.80% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

RED BANK, N.J., Aug. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial r...

2 months ago - PRNewsWire

Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

RED BANK, N.J., July 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it w...

2 months ago - PRNewsWire

PRVB Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Couns...

New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between Novembe...

3 months ago - Newsfile Corp

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Enco...

Los Angeles, California--(Newsfile Corp. - July 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (...

3 months ago - Newsfile Corp

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and ...

New York, New York--(Newsfile Corp. - July 19, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Pro...

3 months ago - Newsfile Corp

PRVB Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Le...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Compa...

3 months ago - Business Wire

PRVB TUESDAY DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors to Secure Counsel B...

New York, New York--(Newsfile Corp. - July 19, 2021) - WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between Novemb...

3 months ago - Newsfile Corp

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and E...

Los Angeles, California--(Newsfile Corp. - July 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (...

3 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of...

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its o...

3 months ago - PRNewsWire

FINAL DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before ...

NEW YORK, July 16, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and A...

3 months ago - PRNewsWire

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a L...

New York, New York--(Newsfile Corp. - July 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRV...

3 months ago - Newsfile Corp

PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.

New York, New York--(Newsfile Corp. - July 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Provention Bio, Inc....

3 months ago - Newsfile Corp

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention...

LOS ANGELES--(BUSINESS WIRE)---- $PRVB #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)

3 months ago - Business Wire

TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc....

Los Angeles, California--(Newsfile Corp. - July 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (...

3 months ago - Newsfile Corp

Is Provention Bio a Bad News Buy?

There's a good case this biotech stock is now at least somewhat undervalued.

3 months ago - The Motley Fool

PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Beha...

New York, New York--(Newsfile Corp. - July 15, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) allegin...

3 months ago - Newsfile Corp

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and ...

New York, New York--(Newsfile Corp. - July 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Prov...

3 months ago - Newsfile Corp

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio,...

LOS ANGELES, July 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on beha...

3 months ago - PRNewsWire

TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, In...

Los Angeles, California--(Newsfile Corp. - July 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (...

3 months ago - Newsfile Corp

Rosen, Global Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 ...

New York, New York--(Newsfile Corp. - July 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between Novembe...

3 months ago - Newsfile Corp